HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma.

Abstract
This phase II study evaluated the efficacy and safety of AMG 102 (rilotumumab), a fully human monoclonal antibody against hepatocyte growth factor/scatter factor (HGF/SF), in patients with recurrent glioblastoma (GBM). Patients with histologically confirmed, measurable recurrent GBM or gliosarcoma (World Health Organization grade 4) and ≤3 relapses or prior systemic therapies received AMG 102 (10 or 20 mg/kg) by infusion every 2 weeks. The primary endpoint was best confirmed objective response rate (central assessment) per Macdonald criteria. Of the 61 patients who enrolled, 60 received AMG 102. Twenty-nine patients (48%) had previously received bevacizumab. There were no objective responses per central assessment, but 1 patient had an objective response per investigator assessment. Median overall survival (95% CI) in the 10- and 20-mg/kg cohorts was 6.5 months (4.1-9.8) and 5.4 months (3.4-11.4), respectively, and progression-free survival (PFS) per central assessment was 4.1 weeks (4.0-4.1) and 4.3 weeks (4.1-8.1), respectively. PFS was similar among patients who had previously received bevacizumab compared with bevacizumab-naive patients. The most common adverse events were fatigue (38%), headache (33%), and peripheral edema (23%). AMG 102 serum concentrations increased approximately dose-proportionally with 2-fold accumulation at steady state. Plasma total HGF/SF and soluble c-Met concentrations increased 12.05- and 1.12-fold, respectively, from baseline during AMG 102 treatment. AMG 102 monotherapy at doses up to 20 mg/kg was not associated with significant antitumor activity in heavily pretreated patients with recurrent GBM.
AuthorsPatrick Y Wen, David Schiff, Timothy F Cloughesy, Jeffrey J Raizer, John Laterra, Melanie Smitt, Michael Wolf, Kelly S Oliner, Abraham Anderson, Min Zhu, Elwyn Loh, David A Reardon
JournalNeuro-oncology (Neuro Oncol) Vol. 13 Issue 4 Pg. 437-46 (Apr 2011) ISSN: 1523-5866 [Electronic] England
PMID21297127 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • rilotumumab
  • Hepatocyte Growth Factor
  • Proto-Oncogene Proteins c-met
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (pharmacokinetics, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor (blood)
  • Brain Neoplasms (blood, drug therapy)
  • Female
  • Glioblastoma (blood, drug therapy)
  • Hepatocyte Growth Factor (blood)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (blood, drug therapy)
  • Proto-Oncogene Proteins c-met (blood)
  • Survival Rate
  • Tissue Distribution
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: